Lupus Clinical Trials in San Jose, CA

13 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor	Phase 1/2	Alice Bertaina	16 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)	Phase 2	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	16 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	16 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE	Phase 1/2	AstraZeneca	17 mi
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis	Phase 2	Autolus Limited	17 mi
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease	Phase 1	CRISPR Therapeutics	22 mi
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus	Phase 3	AstraZeneca	31 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Phase 3	UCB Biopharma SRL	31 mi
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)	Phase 2	Novartis Pharmaceuticals	42 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study	Phase 2	Children's Hospital Medical Center, Cincinnati	42 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease	Phase 1	Fate Therapeutics	42 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants	Phase 2	Hoffmann-La Roche	42 mi
VIBRANT: VIB4920 for Active Lupus Nephritis	Phase 2	National Institute of Allergy and Infectious Diseases (NIAID)	42 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.